Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
1.
J Clin Virol ; 105: 49-56, 2018 08.
Article in English | MEDLINE | ID: mdl-29886373

ABSTRACT

BACKGROUND: The current treatment options for hepatitis C virus (HCV), based on direct acting antivirals (DAA), are dependent on virus genotype and previous treatment experience. Treatment failures have been associated with detection of resistance-associated substitutions (RASs) in the DAA targets of HCV, the NS3, NS5A and NS5 B proteins. OBJECTIVE: To develop a next generation sequencing based method that provides genotype and detection of HCV NS3, NS5A, and NS5 B RASs without prior knowledge of sample genotype. STUDY DESIGN: In total, 101 residual plasma samples from patients with HCV covering 10 different viral subtypes across 4 genotypes with viral loads of 3.84-7.61 Log IU/mL were included. All samples were de-identified and consequently prior treatment status for patients was unknown. Almost full open reading frame amplicons (∼ 9 kb) were generated using RT-PCR with a single primer set. The resulting amplicons were sequenced with high throughput sequencing and analysed using an in-house developed script for detecting RASs. RESULTS: The method successfully amplified and sequenced 94% (95/101) of samples with an average coverage of 14,035; four of six failed samples were genotype 4a. Samples analysed twice yielded reproducible nucleotide frequencies across all sites. RASs were detected in 21/95 (22%) samples at a 15% threshold. The method identified one patient infected with two genotype 2b variants, and the presence of subgenomic deletion variants in 8 (8.4%) of 95 successfully sequenced samples. CONCLUSIONS: The presented method may provide identification of HCV genotype, RASs detection, and detect multiple HCV infection without prior knowledge of sample genotype.


Subject(s)
Drug Resistance, Viral/genetics , Genotyping Techniques , Hepacivirus/genetics , High-Throughput Nucleotide Sequencing/methods , Open Reading Frames , Viral Nonstructural Proteins/genetics , Genetic Variation , Genotype , Hepatitis C/blood , Humans , Phylogeny , Sequence Analysis, DNA
2.
Psychol Med ; 46(6): 1151-61, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26743873

ABSTRACT

BACKGROUND: In depression, non-remission, recurrence of depressive episodes after remission and conversion to bipolar disorder are crucial determinants of poor outcome. The present study aimed to determine the cumulative incidences and clinical predictors of these long-term outcomes after the first lifetime episode of depression. METHOD: A total of 301 in- or out-patients aged 18-70 years with a validated diagnosis of a single depressive episode were assessed from 2005 to 2007. At 5 years of follow-up, 262 patients were reassessed by means of the life chart method and diagnostic interviews from 2011 to 2013. Cumulative incidences and the influence of clinical variables on the rates of remission, recurrence and conversion to bipolar disorder, respectively, were estimated by survival analysis techniques. RESULTS: Within 5 years, 83.3% obtained remission, 31.5% experienced recurrence of depression and 8.6% converted to bipolar disorder (6.3% within the first 2 years). Non-remission increased with younger age, co-morbid anxiety and suicidal ideations. Recurrence increased with severity and treatment resistance of the first depression, and conversion to bipolar disorder with treatment resistance, a family history of affective disorder and co-morbid alcohol or drug abuse. CONCLUSIONS: The identified clinical characteristics of the first lifetime episode of depression should guide patients and clinicians for long-term individualized tailored treatment.


Subject(s)
Bipolar Disorder/epidemiology , Depression/therapy , Adolescent , Adult , Aged , Anxiety/complications , Comorbidity , Depression/complications , Female , Follow-Up Studies , Humans , Inpatients/psychology , Kaplan-Meier Estimate , Male , Middle Aged , Outpatients/psychology , Proportional Hazards Models , Prospective Studies , Psychiatric Status Rating Scales , Recurrence , Remission Induction , Severity of Illness Index , Suicidal Ideation , Young Adult
3.
Transl Psychiatry ; 5: e631, 2015 Sep 01.
Article in English | MEDLINE | ID: mdl-26327689

ABSTRACT

The serotonin-transporter-linked polymorphic region (5-HTTLPR) is one of the most extensively investigated candidates to be involved in gene-environment interaction associated with depression. Nevertheless, the interaction remains controversial. In an original study, we tested the hypothesis that risk for use of antidepressants following a diagnosis of colorectal cancer is associated with bi- and triallelic genotypes of 5-HTTLPR. In addition, in an inclusive meta-analysis, we tested the hypothesis that depression following a diagnosis of cancer is associated with biallelic 5-HTTLPR genotype. We created an exposed-only cohort of 849 colorectal cancer patients from the Danish Diet, Cancer and Health cohort study. The hypothesized association was investigated with Cox regression models and competing risk analyses. Five studies comprising a total of 1484 cancer patients were included in the meta-analysis. Nationwide registries provided information on dates of diagnosis of colorectal cancer and use of antidepressants. Unadjusted odds ratios of depression according to the biallelic 5-HTTLPR genotype were included in the meta-analysis. 5-HTTLPR genotypes were not associated with use of antidepressants after colorectal cancer. Estimated hazard ratios ranged 0.92-1.08, and we observed no statistically significant associations across biallelic and triallelic genotypes in crude as well as adjusted models. The meta-analysis showed no statistically significant associations of 5-HTTLPR biallelic genotype with depression after cancer. Our findings in an original study and a meta-analysis do not support the hypothesis of an association between the 5-HTTLPR genotype and depression after cancer.


Subject(s)
Antidepressive Agents/therapeutic use , Colorectal Neoplasms/complications , Colorectal Neoplasms/psychology , Depressive Disorder/drug therapy , Depressive Disorder/genetics , Serotonin Plasma Membrane Transport Proteins/genetics , Depressive Disorder/complications , Humans
4.
J Viral Hepat ; 21(8): 578-84, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24224717

ABSTRACT

We evaluated the effects of genetic variation in toll-like receptors (TLR), retinoic acid-inducible gene I (RIG-I) and their signalling pathways on spontaneous hepatitis C virus (HCV) resolution. We screened 95 single-nucleotide polymorphisms (SNPs) in 22 genes. SNPs significantly associated with resolution in the discovery cohort were genotyped in a validation cohort. Multivariate logistic regression adjusted for sex, hepatitis B surface antigen, HIV infection and the interleukin-28B rs12979860 SNP was performed in the combined cohort. Haplotype reconstruction and linkage disequilibrium analysis were performed. srs2233437, rs730775 and rs28362857 in Inhibitor of NF-kB ε (IkBε) and rs352140 in TLR9 were associated with spontaneous HCV resolution (P ≤ 0.05) in the discovery cohort (n = 308). In the validation cohort (n = 216), we replicated a significant association with HCV resolution for two SNPs in the IkBε, rs2233437 and rs730775. Presence of one or two of the variant allele in rs2233437 had more than twofold higher odds of resolution in adjusted logistic regression (adjusted odds ratio (aOR), 2.6; (95% CI, 1.4, 4.8) P = 0.002). We identified polymorphisms in the IkBε gene associated with spontaneous HCV resolution in two independent cohorts.


Subject(s)
DEAD-box RNA Helicases/genetics , Disease Resistance , Hepatitis C/genetics , Hepatitis C/immunology , I-kappa B Kinase/genetics , Signal Transduction/genetics , Toll-Like Receptors/genetics , Adult , Cohort Studies , DEAD Box Protein 58 , Female , Genetic Association Studies , Genetic Variation , Haplotypes , Humans , Linkage Disequilibrium , Male , Middle Aged , Polymorphism, Single Nucleotide , Receptors, Immunologic
5.
J Viral Hepat ; 18(4): e66-74, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21070502

ABSTRACT

Twenty-five per cent of individuals infected with hepatitis C virus (HCV) are able to clear HCV spontaneously. Differences in host genetics are believed to affect the outcome of HCV infection. We analysed an exonic, a promoter and an intronic single nucleotide polymorphism (SNP) of the interferon-λ3 coding interleukin (IL)-28B gene to study the relationship between IL28B SNPs and outcome of HCV infection. Among 206 HIV-1-infected Europeans with evidence of HCV infection, 47 (23%) individuals had cleared HCV and 159 (77%) had developed chronic infection. The exonic rs8103142 CT, the promoter rs12979860 CT and the intronic rs11881222 AG genotypes were associated with a decreased HCV clearance rate with adjusted odds ratios (aOR) of 0.3 (95% CI, 0.1-0.7), 0.4 (95% CI, 0.2-0.8) and 0.4 (95% CI, 0.2-0.8), respectively. The haplotype block TCG CTA was associated with a decreased HCV clearance rate (aOR 0.4, 95% CI, 0.2-0.8). Further, we found significant differences in HCV RNA levels among individuals chronically infected with HCV genotype 1 for rs8103142 and rs12979860 (P ≤ 0.05). Chronically infected individuals with HCV genotype 3 and with the favourable haplotype block CTA CTA had higher median HCV RNA levels than individuals with unfavourable haplotype blocks (P ≤ 0.05). Our findings suggest that IL28B may account for some differences in HCV outcome but that other factors including the viral genotype, host genetics and the host-virus interaction are likely to influence the outcome of HCV infection.


Subject(s)
Hepacivirus/immunology , Hepacivirus/isolation & purification , Hepatitis C/immunology , Hepatitis C/virology , Interleukins/genetics , Polymorphism, Single Nucleotide , Viral Load , Adult , Female , Gene Frequency , HIV Infections/complications , Haplotypes , Humans , Interferons , Male , Treatment Outcome
6.
J Viral Hepat ; 16(9): 659-65, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19486467

ABSTRACT

Predictive factors for initiation of antiviral therapy in chronically infected hepatitis C virus (HCV) patients are not fully elucidated. The aim of this study was to determine predictive factors for initiation of treatment with standard or pegylated interferon either alone or combined with ribavirin. A Danish cohort of individuals chronically infected with HCV was used and observation time was calculated from the date of inclusion in the cohort to date of death, last clinical observation, 1 January 2007, or start of HCV antiviral treatment in treatment-naïve patients. Kaplan-Meier survival analysis was used to construct time to event curves. Cox regression was used to determine the incidence rate ratios as estimates of relative risk (RR) and 95% confidence intervals (CI). A total of 1780 patients were enrolled in the study. The cumulative chance of treatment initiation over 5 years was 33.0%. We found several strong predictors of treatment initiation: elevated alanine aminotransferase [>2 times upper limit (RR = 2.17, 95% CI 1.64-2.87), >3 times upper limit (RR = 3.64, 95% CI 2.75-4.81)], genotype 2 or 3 (RR = 1.86, 95% CI 1.49-2.31) and HIV co-infection (RR = 0.28, 95% CI 0.15-0.53). To our knowledge, this study is the first to estimate factors predicting initiation of antiviral treatment in patients with chronic HCV infection on a nationwide scale. We found that several of the factors predicting initiation of antiviral treatment correlate with factors known to predict a better response to treatment and factors known to increase the progression of liver disease.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/drug therapy , Adult , Biomarkers , Cohort Studies , Denmark , Female , Humans , Interferons/therapeutic use , Male , Middle Aged , Models, Statistical , Prognosis , Ribavirin/therapeutic use , Young Adult
7.
J Viral Hepat ; 16(9): 621-32, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19302336

ABSTRACT

Cell entry by enveloped viruses is mediated by viral glycoproteins, and generally involves a short hydrophobic peptide (fusion peptide) that inserts into the cellular membrane. An internal hydrophobic domain within E1 (aa262-290) of hepatitis C virus (HCV) may function as a fusion peptide. Retrovirus-based HCV-pseudotyped viruses (HCVpp; genotype 1a) containing Ala or Pro substitutions at conserved amino acid positions within this putative fusion peptide were generated. Mutation of conserved residues significantly reduced efficiency of HCVpp entry into Huh-7 cells. The majority of amino acid substitutions appeared to disrupt necessary interactions between E1 and E2. For some mutants, reductions in HCVpp-associated E1 were associated with the incorporation of a high molecular weight, hyperglycosylated E2 that displayed decreased CD81-binding. Other entry-deficient mutants displayed normal E1E2 incorporation into pseudoparticles and normal CD81-binding, and therefore might affect viral fusion. One mutant (S283P) consistently displayed two- to threefold higher infectivity than did wild-type. Three mutations that decreased HCVpp infectivity also reduced levels of HCVcc infectious virus production. However, the S283P mutation had a different effect in the two systems as it did not increase production of infectious HCVcc. This comprehensive mutational analysis of the putative HCV fusion peptide provides insight into the role of E1 in its interaction with E2 and in HCV entry.


Subject(s)
Genetic Vectors , Hepacivirus/physiology , Retroviridae/genetics , Viral Envelope Proteins/genetics , Virion/genetics , Virus Internalization , Amino Acid Substitution , Antigens, CD/metabolism , Cell Line , Hepacivirus/genetics , Humans , Mutagenesis, Site-Directed , Mutant Proteins/genetics , Mutant Proteins/physiology , Protein Binding , Recombination, Genetic , Tetraspanin 28 , Viral Envelope Proteins/metabolism , Viral Envelope Proteins/physiology
8.
J Med Virol ; 65(4): 694-7, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11745933

ABSTRACT

GB virus-B (GBV-B) is a member of the Flaviviridae family of viruses. This RNA virus causes acute resolving hepatitis in experimentally infected tamarins, but its natural host remains unknown. GBV-B and a related virus, GBV-A, were recovered from serum containing the "GB agent," which was believed to have originated from a surgeon (initials: GB) with acute hepatitis. GBV-B has special interest because it is the virus related most closely to hepatitis C virus, which is an important cause of acute and chronic liver disease in humans. In the present study, we found that the host range of GBV-B includes owl monkeys. Tamarins and owl monkeys belong to two different families of New World monkeys. The natural history of GBV-B in the two owl monkeys studied was similar to that previously found for tamarins and was characterized by early appearance of viremia and viral clearance. However, the peak viral titers of GBV-B observed in owl monkeys (10(5) genome equivalents [GE] /ml) were lower than those observed in experimentally infected tamarins (10(7)-10(8) GE/ml) and acute hepatitis was observed in only one animal. If GBV-B were indeed a virus of humans, it would be expected to infect chimpanzees, a surrogate of humans, because all recognized human hepatitis viruses are transmissible to chimpanzees and cause hepatitis. However, in the present study, we failed to transmit GBV-B to a naive chimpanzee. In addition, a second naive chimpanzee transfected intrahepatically with RNA transcripts from an infectious clone of GBV-B did not become infected. Thus, chimpanzees are apparently not susceptible to GBV-B. Finally, we failed to detect GBV-B in acute-phase serum from surgeon GB. Our data suggest that GBV-B is not a human virus and that GBV-B, like GBV-A, is a virus of New World monkeys.


Subject(s)
Ape Diseases/virology , Flaviviridae Infections/veterinary , GB virus C , Hepatitis, Viral, Animal/virology , Monkey Diseases/virology , Acute Disease , Animals , Aotidae , GB virus C/pathogenicity , Pan troglodytes , Species Specificity , Viremia
9.
Proc Natl Acad Sci U S A ; 98(20): 11609-14, 2001 Sep 25.
Article in English | MEDLINE | ID: mdl-11562506

ABSTRACT

Identification of previously unrecognized viral agents in serum or plasma samples is of great medical interest but remains a major challenge, primarily because of abundant host DNA. The current methods, library screening or representational difference analysis (RDA), are very laborious and require selected sample sets. We have developed a simple and reproducible method for discovering viruses in single serum samples that is based on DNase treatment of the serum followed by restriction enzyme digestion and sequence-independent single primer amplification (SISPA) of the fragments, and have evaluated its performance on known viruses. Both DNA viruses and RNA viruses at a concentration of approximately 10(6) genome equivalents per ml were reproducibly identified in 50 microl of serum. While evaluating the method, two previously unknown parvoviruses were discovered in the bovine sera used as diluent. The near complete genome sequence of each virus was determined; their classification as two species (provisionally named bovine parvoviruses 2 and 3) was confirmed by phylogenetic analysis. Both viruses were found to be frequent contaminants of commercial bovine serum. DNase treatment of serum samples may prove to be a very useful tool for virus discovery. The DNase-SISPA method is suitable for screening of a large number of samples and also enables rapid sequence determination of high-titer viruses.


Subject(s)
Deoxyribonucleases/metabolism , Parvovirus/isolation & purification , Animals , Base Sequence , Cattle , DNA, Viral/genetics , DNA, Viral/isolation & purification , Molecular Sequence Data , Open Reading Frames , Parvovirus/classification , Parvovirus/enzymology , Phylogeny , Polymerase Chain Reaction , RNA, Viral/genetics , RNA, Viral/isolation & purification , Restriction Mapping
10.
J Virol Methods ; 97(1-2): 113-23, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11483222

ABSTRACT

A chimeric cDNA genome was constructed in which the core, E1 and E2 genes of hepatitis C virus (HCV) replaced the core, E(rns), E1 and E2 genes of bovine viral diarrhea virus (BVDV). High levels of HCV structural proteins were expressed in a small number of human or bovine cells following transfection with chimeric RNA. However, in one cell line, bovine embryonic trachea cells [EBTr(A)], the number of cells expressing HCV proteins increased to greater than 70% following serial passage of culture medium. These cells were persistently infected with a non-cytopathogenic BVDV helper virus. In these cells, the chimeric genome was packaged into infectious particles that accumulated in the culture medium at a titer as high as 10(7)-10(9) genome equivalents per ml. The virus particles were pseudotypes, because they were neutralized by anti-BVDV but not by anti-HCV.


Subject(s)
Diarrhea Viruses, Bovine Viral/genetics , Gene Expression Regulation, Viral , Genetic Engineering , Hepacivirus/genetics , Viral Structural Proteins/biosynthesis , Animals , Antibodies, Viral/immunology , Blotting, Western , Cattle , DNA, Recombinant/genetics , Diarrhea Viruses, Bovine Viral/immunology , Diarrhea Viruses, Bovine Viral/physiology , Genome, Viral , Helper Viruses/genetics , Helper Viruses/physiology , Hepacivirus/physiology , Humans , Immune Sera/immunology , Microscopy, Fluorescence , Radioimmunoprecipitation Assay , Transfection , Tumor Cells, Cultured , Viral Structural Proteins/genetics , Virus Replication
11.
Intervirology ; 44(2-3): 132-42, 2001.
Article in English | MEDLINE | ID: mdl-11509874

ABSTRACT

Persistent infection with hepatitis C virus (HCV) is an important cause of chronic liver disease worldwide. Therefore, the development of vaccines to prevent HCV infection, or at least to prevent progression to chronicity, is a major goal. Potential HCV vaccine candidates include recombinant proteins, recombinant viruses, DNA constructs, synthetic peptides and virus-like particles. Various vaccine candidates have been shown to generate humoral and cellular immune responses in animals, primarily in mice. However, the efficacy of most vaccine candidates in protecting against HCV has not been tested because the chimpanzee, the only animal other than humans that is susceptible to HCV, is not readily available, requires special facilities, and is very expensive. The course of infection in chimpanzees is similar in its diversity to that in humans and detailed studies in this model are beginning to define the immune responses that can terminate HCV infection. Of relevance for vaccine evaluation was the titration in chimpanzees of different HCV variants to provide well-characterized challenge pools. In addition, monoclonal virus pools generated from chimpanzees infected with cloned viruses make it possible now to examine immunity to HCV without the confounding factor of antigenic diversity of the challenge virus (quasispecies). The vaccine trials performed in chimpanzees to date all have tested the efficacy of immunizations with various forms of the envelope proteins of HCV.


Subject(s)
Hepacivirus/immunology , Hepatitis C/immunology , Pan troglodytes/immunology , Pan troglodytes/virology , Viral Hepatitis Vaccines/immunology , Viral Hepatitis Vaccines/therapeutic use , Animals , Clinical Trials as Topic/veterinary , Disease Models, Animal , Hepacivirus/genetics , Hepacivirus/physiology , Hepatitis C/blood , Hepatitis C Antibodies/biosynthesis , Hepatitis C Antibodies/immunology , Humans , Neutralization Tests , Vaccination
12.
J Viral Hepat ; 8(3): 228-31, 2001 May.
Article in English | MEDLINE | ID: mdl-11380802

ABSTRACT

The chimpanzee is the only recognized animal model for the study of hepatitis C virus (HCV). However, recently it was reported that rhesus monkeys were susceptible to HCV and developed hepatitis during infection. In the present study, we inoculated two rhesus monkeys each with HCV strain H77 (genotype 1a), strain HC-J6 (genotype 2a) or strain S52 (genotype 3a). Weekly serum samples were tested for liver enzyme values, HCV antibodies and HCV RNA. We did not find evidence of HCV infection in any of the monkeys during 24 weeks of follow-up. Our study demonstrates that rhesus monkeys are not readily infected with HCV and apparently do not represent a useful animal model for the study of HCV.


Subject(s)
Hepacivirus/genetics , Hepatitis C/veterinary , Macaca mulatta/virology , Animals , Antibodies, Viral/blood , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Hepacivirus/immunology , Hepacivirus/pathogenicity , Hepatitis C/blood , Hepatitis C/pathology , Macaca mulatta/blood , RNA, Viral/blood , Reverse Transcriptase Polymerase Chain Reaction
13.
Proc Natl Acad Sci U S A ; 97(24): 13318-23, 2000 Nov 21.
Article in English | MEDLINE | ID: mdl-11078521

ABSTRACT

Persistent infection with hepatitis C virus (HCV) is among the leading causes of chronic liver disease. Previous studies suggested that genetic variation in hypervariable region 1 (HVR1) of the second envelope protein, possibly in response to host immune pressure, influences the outcome of HCV infection. In the present study, a chimpanzee transfected intrahepatically with RNA transcripts of an infectious HCV clone (pCV-H77C) from which HVR1 was deleted became infected; the DeltaHVR1 virus was subsequently transmitted to a second chimpanzee. Infection with DeltaHVR1 virus resulted in persistent infection in the former chimpanzee and in acute resolving infection in the latter chimpanzee. Both chimpanzees developed hepatitis. The DeltaHVR1 virus initially replicated to low titers, but virus titer increased significantly after mutations appeared in the viral genome. Thus, wild-type HCV without HVR1 was apparently attenuated, suggesting a functional role of HVR1. However, our data indicate that HVR1 is not essential for the viability of HCV, the resolution of infection, or the progression to chronicity.


Subject(s)
Hepacivirus/genetics , Hepacivirus/pathogenicity , Hepatitis C/physiopathology , Viral Proteins/genetics , Animals , Biological Evolution , Genes, env , Mutagenesis , Open Reading Frames , Pan troglodytes , RNA, Viral/genetics , Sequence Deletion , Transfection
14.
Virology ; 277(2): 358-67, 2000 Nov 25.
Article in English | MEDLINE | ID: mdl-11080483

ABSTRACT

Since recombinant envelope glycoprotein E2 of hepatitis C virus (HCV) binds to CD81 on human and chimpanzee cells, it has been suggested that CD81 may be a receptor for HCV. Humans and chimpanzees are the only species known to be susceptible to HCV infection. E2 has been reported not to bind to CD81 of the African green monkey, mouse, or rat, suggesting that binding of HCV to CD81 is species specific and may determine susceptibility to infection with HCV. We investigated the interaction between E2 of HCV and CD81 of tamarins, a group of small New World monkeys frequently used for the study of human viruses. Tamarins are not susceptible to HCV infection. Nonetheless, we found that three different forms of HCV E2 (intracellular, secreted, and cell surface-displayed) bound more efficiently to recombinant tamarin CD81 than to human CD81, as determined by ELISA and immunofluorescence. The affinity of the interaction was approximately 10-fold higher for tamarin than for human CD81. Binding of E2 to CD81 on cultured or primary tamarin cells was demonstrated by flow cytometry. In contrast to previous reports, there was also a low-affinity interaction between E2 and African green monkey CD81. Thus, the HCV E2 interaction with CD81 is not limited to humans and chimpanzees and does not predict susceptibility to HCV infection.


Subject(s)
Antigens, CD/immunology , Hepacivirus/metabolism , Membrane Glycoproteins/immunology , Membrane Proteins , Receptors, Virus/metabolism , Saguinus/immunology , Viral Envelope Proteins/immunology , Amino Acid Sequence , Animals , Antigens, CD/biosynthesis , Antigens, CD/genetics , Cells, Cultured , Chimera/immunology , Chlorocebus aethiops , Flow Cytometry , Fluorescent Antibody Technique , Hepacivirus/immunology , Humans , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Molecular Sequence Data , Protein Binding , Receptors, Virus/biosynthesis , Receptors, Virus/genetics , Recombinant Proteins/metabolism , Species Specificity , Tetraspanin 28
15.
Hepatology ; 32(3): 618-25, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10960458

ABSTRACT

Hepatitis C virus (HCV) is an important cause of chronic liver disease worldwide. Development of vaccines to prevent HCV infection, or at least prevent progression to chronicity, is a major goal. In mice and rhesus macaques, a DNA vaccine encoding cell-surface HCV-envelope 2 (E2) glycoprotein stimulated stronger immune responses than a vaccine encoding intracellular E2. Therefore, we used DNA encoding surface-expressed E2 to immunize chimpanzees 2768 and 3001. Chimpanzee 3001 developed anti-E2 after the second immunization and antibodies to hypervariable region 1 (HVR1) after the third immunization. Although chimpanzee 2768 had only low levels of anti-E2 after the third immunization, an anamnestic response occurred after HCV challenge. CTL responses to E2 were not detected before challenge, but a strong response was detected after HCV challenge in chimpanzee 2768. An E2-specific CD4+ response was detected in chimpanzee 2768 before challenge and in both chimpanzees postchallenge. Three weeks after the last immunization, animals were challenged with 100 50% chimpanzee-infectious doses (CID(50)) of homologous monoclonal HCV. As a control, a naive chimpanzee was inoculated with 3 CID(50) of the challenge virus. The vaccine did not generate sterilizing immunity because both vaccinated chimpanzees were infected. However, both vaccinated chimpanzees resolved the infection early whereas the control animal became chronically infected. Compared with the control animal, hepatitis appeared earlier in the course of the infection in both vaccinated chimpanzees. Therefore, DNA vaccine encoding cell surface-expressed E2 did not elicit sterilizing immunity in chimpanzees against challenge with a monoclonal homologous virus, but did appear to modify the infection and might have prevented progression to chronicity.


Subject(s)
Antibodies, Monoclonal/immunology , DNA/genetics , Hepacivirus/immunology , Hepatitis C/immunology , Hepatitis C/prevention & control , Pan troglodytes/immunology , Plasmids/genetics , Vaccination , Viral Envelope Proteins/genetics , Animals , CD4-Positive T-Lymphocytes/immunology , Female , Hepatitis C/blood , Hepatitis C/physiopathology , T-Lymphocytes, Cytotoxic/immunology
16.
J Infect Dis ; 182(3): 698-707, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10950762

ABSTRACT

Hepatitis C virus (HCV) infection is a major health problem in Egypt, where the seroprevalence is 10-20-fold higher than that in the United States. To characterize the HCV genotype distribution and concordance of genotype assessments on the basis of multiple genomic regions, specimens were obtained from blood donors in 15 geographically diverse governorates throughout Egypt. The 5' noncoding, core/E1, and NS5B regions were amplified by reverse transcription-polymerase chain reaction and analyzed by both restriction fragment length polymorphism (RFLP) and phylogenetic tree construction. For the 5' noncoding region, 122 (64%) of 190 specimens were amplified and analyzed by RFLP: 111 (91%) were genotype 4, 1 (1%) was genotype 1a, 1 (1%) was genotype 1b, and 9 (7%) could not be typed. Phylogenetic analyses of the core/E1 and NS5B regions confirmed the genotype 4 preponderance and revealed evidence of 3 new subtypes. Analysis of genetic distance between isolates was consistent with the introduction of multiple virus strains 75-140 years ago, and no clustering was detected within geographic regions, suggesting widespread dispersion at some time since then.


Subject(s)
Hepacivirus/genetics , Hepatitis C/genetics , Blood Donors , Egypt/epidemiology , Genotype , Hepatitis C/epidemiology , Humans , Phylogeny , Polymorphism, Restriction Fragment Length , RNA-Dependent RNA Polymerase/genetics , Reverse Transcriptase Polymerase Chain Reaction , Seroepidemiologic Studies , Viral Envelope Proteins/genetics , Viral Nonstructural Proteins/genetics
17.
Virology ; 274(1): 75-85, 2000 Aug 15.
Article in English | MEDLINE | ID: mdl-10936090

ABSTRACT

The envelope proteins of hepatitis C virus (HCV) are the likely targets of neutralizing antibodies and their molecular and functional characterization is relevant for vaccine development. We previously showed that surface-expressed E2 is a better immunogen than intracellular E2 and, therefore, we were interested in exploring more efficient ways to present E2 protein on the cell surface. We found that E2 targeted to the cell surface by replacement of its transmembrane domain did not bring E1 to the surface although E1 could be expressed independently on the cell surface if its transmembrane domain was similarly replaced. FACS analysis suggested that E2 expressed on the cell surface acquired its native conformation more efficiently when truncated at aa 661 than when truncated at aa 715. The shorter form of truncated E2 better retained the ability to bind the second extracellular loop (EC2) of CD81, the putative HCV receptor. Interestingly, deletion of the hypervariable region 1 (HVR1) did not perceptibly alter E2 structure; cell-surface forms of E2 lacking the HVR1 remained reactive with conformation-sensitive MAbs and were able to bind recombinant EC2 of CD81.


Subject(s)
Hepacivirus/metabolism , Viral Envelope Proteins/biosynthesis , Amino Acids , Animals , Antigens, CD/genetics , Antigens, CD/metabolism , Biological Transport , Cell Membrane/metabolism , Gene Expression , Hepacivirus/genetics , Humans , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , Mutagenesis , Protein Binding , Protein Conformation , Rabbits , Receptors, Virus/genetics , Receptors, Virus/metabolism , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Tetraspanin 28 , Tumor Cells, Cultured , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/genetics , Viral Envelope Proteins/metabolism , Viral Proteins/genetics , Viral Proteins/metabolism
18.
J Gen Virol ; 81(Pt 4): 1001-7, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10725426

ABSTRACT

A recently discovered DNA virus, TT virus (TTV), is prevalent in humans. In the present study, the genetic heterogeneity of TTV was evaluated in hepatitis C virus (HCV)-infected patients and in chimpanzees. TTV DNA was detected by PCR in serum samples from all ten HCV-infected patients studied; at least five major TTV genotypes, all previously identified in humans, were recovered. Eight patients were infected with multiple variants of TTV. TTV DNA was detected by PCR in serum samples from 11 (65%) of 17 naive chimpanzees bred in captivity; a persistent infection was present in three of six animals. At least five chimpanzees were infected with more than one TTV variant. Detection of TTV DNA in chimpanzee faecal samples suggests the possibility of faecal-oral transmission. Phylogenetic analysis of ORF1 sequences amplified from chimpanzees identified three major genotypes which had not previously been recognized in humans.


Subject(s)
DNA Viruses/genetics , DNA Viruses/isolation & purification , Genome, Viral , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis C/virology , Amino Acid Sequence , Animals , Genes, Viral , Humans , Molecular Sequence Data , Pan troglodytes , Polymerase Chain Reaction , Prevalence
19.
Virology ; 262(2): 470-8, 1999 Sep 30.
Article in English | MEDLINE | ID: mdl-10502525

ABSTRACT

GB virus-B (GBV-B) is a member of the Flaviviridae family of viruses. This RNA virus infects tamarins, but its natural host is not known. GBV-B has special interest because it is the virus that is most closely related to hepatitis C virus (HCV), an important human pathogen. In the present study, we identified a previously unrecognized sequence at the 3' end of the GBV-B genome. This new 3' terminal sequence can form several predicted stem-loop structures as is typical for other members of the Flaviviridae family. We constructed molecular clones and showed that the new 3' UTR sequence was critical for in vivo infectivity. After intrahepatic transfection of two tamarins with RNA transcripts of the full-length GBV-B clone, we detected high viral titers from Week 1 postinoculation with peak titers of approximately 10(8) genome equivalents/ml. The viremic pattern of GBV-B infection in the transfected animals was the same as in animals inoculated intravenously with the virus pool used as the cloning source. The sequence of the recombinant virus was recovered from one of the tamarins and shown to be identical to that of the infectious clone. The development of severe hepatitis in both tamarins infected with the recombinant GBV-B virus provides formal proof that GBV-B is a true hepatitis virus.


Subject(s)
3' Untranslated Regions/genetics , Disease Models, Animal , Flaviviridae/genetics , Flaviviridae/pathogenicity , Hepacivirus/genetics , Hepatitis, Viral, Animal/virology , Saguinus/virology , 3' Untranslated Regions/chemistry , 3' Untranslated Regions/physiology , Animals , Base Sequence , Cloning, Molecular , Consensus Sequence/genetics , Flaviviridae/growth & development , Hepatitis C/virology , Liver/virology , Nucleic Acid Conformation , RNA, Viral/chemistry , RNA, Viral/genetics , Sequence Analysis, DNA , Sequence Homology, Nucleic Acid , Viremia
20.
Virology ; 262(1): 250-63, 1999 Sep 15.
Article in English | MEDLINE | ID: mdl-10489358

ABSTRACT

Of the six major genotypes of hepatitis C virus (HCV), infectious cDNA clones of only genotype 1 have been reported. Here, we report the construction of an infectious cDNA clone representing a second major HCV genotype, genotype 2. This infectious clone (pJ6CF) encodes the consensus polyprotein of strain HC-J6(CH), genotype 2a. Its encoded polyprotein differs from those of the infectious clones of genotypes 1a and 1b by approximately 30%. Intertypic chimeric cDNA clones constructed from infectious clones of genotypes 1a and 2a of HCV were not infectious. RNA transcripts of four chimeras containing the 2a structural genes (C, E1, and E2) in the backbone of an infectious genotype 1a clone (pCV-H77C) were not viable in a chimpanzee regardless of whether p7 was from the 1a or 2a clone. However, the chimpanzee was subsequently infected with RNA transcripts of each of the two infectious parent clones, indicating that the inability of the chimeras to replicate was intrinsic to the clones and not the result of preexisting protective immune responses.


Subject(s)
Hepacivirus/genetics , Hepacivirus/pathogenicity , Hepatitis C/genetics , RNA, Viral/genetics , 3' Untranslated Regions/genetics , 5' Untranslated Regions/genetics , Amino Acid Sequence , Animals , Cloning, Molecular , Genotype , Hepatitis C/pathology , Humans , Molecular Sequence Data , Pan troglodytes , RNA/genetics , Recombinant Fusion Proteins/genetics , Sequence Alignment , Viral Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...